Human T-lymphotrophic virus type 1 (HTLV-1) is a causative agent of tropic spastic paraparesis and adult Tcell leukaemia, Information regarding the involvement of HTLV-1 in presentation of some subclinical immune suppression that may results in increased rate of HIV and TB infections has long been documented. Sixty (60) Confirmed Pulmonary TB subjects consisting of 41 males and 19 females were recruited in this study, Tuberculosis was confirmed by collecting their sputum samples and analysed using GeneXpert. The prevalence of HTLV-1 IgG antibodies among TB subjects was 6.6%, while that of IgM was 1.6%. Accordingly, sexually active couple group has the highest prevalence of 2.3% when compared to single and widow categories, age group 15-24 has the highest percentage of 3.3% for HTLV-1 IgG antibodies.
INTRODUCTION
The human T-lymphotropic virus, or human T-cell leukaemia-lymphoma virus (HTLV) belongs to the family of viruses that are known to cause a type of cancer called adult T-cell leukaemia/lymphoma and a diseases called HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP). The HTLV-1 genome is diploid, composed of two copies of a singlestranded RNA virus whose genome is copied into a double-stranded DNA form that integrates into the host cell genome, at which point the virus is referred to as provirus (1) .
Human T-cell lymphotropic virus type 1 (HTLV-1) is a human retrovirus that causes persistent infection in the host. While most infected persons remain asymptomatic carriers (ACs), 3-5% develop a T-cell malignancy termed adult T-cell Luekemia (ATL), and another 0.25-3% develop a chronic progressive inflammatory neurologic disease known as HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) (2) . An increased prevalence of the virus infection among individuals with active TB and higher mortality in co-infected individuals are described by several authors (3). However, contradictory results are reported in other studies (4, 5) . Furthermore, high frequencies of HTLV-1 infection among TB patients have been reported in Japan, Nigeria and Brazil (6, 7, 8) . On the other hand, in studies conducted in Senegal and Papua New Guinea, few TB patients were HTLV-1 infected (9, 10) . Fewer studies started with HTLV-1-infected individuals and looked at the occurrence of TB. In one Japanese report, TB history was more frequent among HTLV-1-infected than among seronegative men (11) In another Japanese study, chest X-ray findings compatible with old pulmonary TB were more frequent among HTLV-1 carriers than among non-carriers (12) . The present research aimed at reporting prevalence of HTLV-1 antibodies among patients infected with pulmonary Tuberculosis (PTB)
MATERIALS AND METHODS

Study Design
The present study is a cross-sectional study.
Study Population
Sixty (60) individuals infected PTB with no history of other chronic diseases were recruited in this study.
Specimen Collection
About 5mls of whole blood was collected aseptically from each subject using standard venepuncture. Samples were dispensed into appropriately labelled screw -capped containers and was left at room temperature for about an hour, after which it was spun at 3,000 rpm for 10minites to separate serum from blood clot. Serum were dispensed into corresponding labelled plain containers and was stored at -20 0 c until needed for assay
Determination of Tuberculosis
Tubercule bacilli was confirmed using GeneXpert as follows; 2 volumes of sample reagent was mixed with one part of sample (Ratio 2:1), It was mixed vigorously 20 times, incubation at room temperature for 10 minutes and mixed again until sample liquefies. 2mls of sample was transferred into the open port of Xpert MTB/RIF Cartridge and lid closed, after 30 minutes, cartridge Barcode was scanned using barcode reader of the machine. Instrument module door was opened with the blinking green light and load cartridge. And the result was recorded.
ELISA technique for HTLV-1 Determination
Fifty (50µl) of negative and positive controls were added to the negative and positive control wells respectively. In sample wells, 40µl Sample dilution buffer and 10µl sample were added. Samples were loaded onto the bottom without touching the well wall and mix well with gentle shaking. After 30 minutes of incubation at room temperature and sealed with closure plate membrane, diluted with buffer 30 times for 96T and washed 5 times. 50µl HRP-Conjugate reagent was added to each well except the blank control well, it was incubated for 30 minutes and washed. 50µl Chromogen Solution A and B were added to each well, mixed with gentle shaking and incubated at 37 ℃ for 15 minutes, light was avoided during colouring. Lastly, 50µl of stop solution was added to each well to terminate the reaction and colour in the well changed from blue to yellow. Absorbance was Read at 450nm using a Microtiter Plate Reader and OD value of the blank control well is set as zero.
Ethical Clearance
An ethical approval was obtained from Jigawa State Ministry of health ethical committee before the commencement of the study, and the consent/accent of the subjects was sought for during this study. The subject was giving an opportunity to accept or reject enrolment into the study.
Statistical Analysis
The results were entered in Microsoft Excel and later transferred in statistical software SPSS Version 20 and OpenEpi version 2.3 for analysis. Table 1 shows the prevalence of HTLV-1 IgG and IgM antibodies among the Pulmonary Tuberculosis patients. Of the sixty screened patients 6.6% that is 4 tested positive to HTLV-1 IgG antibodies while 1.6% that is 1 patient tested positive to IgM antibodies. The statistical analysis shows that there is no significant difference between IgG and IgM antibodies among Tuberculosis patients enrolled in this study with p-value >0.005. 
RESULTS
DISCUSSION
According to the results obtained from the present study, a percentage prevalence of 6.6% for IgG and 1.6% IgM antibodies among TB patients were recorded, this is in accordance with work of Olaleye et al. 1994 (13) who reported a prevalence of 3.6%. Degree of subclinical immunosuppression caused by HTLV-1 infection has been documented by Goon et al., 2004 (14) resulting to other maladies such as crusted scabies, strongyloidiasis and Tuberculosis (15, 8) . In this study the percentage prevalence of participants who are Tuberculosis and HTLV-1 coinfected was 6.6% for IgG antibodies. A study conducted in Salvador a city with highest prevalence of HTLV-1 in Brazil, found that 11% of patients hospitalised with Tuberculosis were infected with HTLV-1 (16 
CONCLUSION
Conclusively, the present research revealed a 6.6% and 1.3% prevalence of HTLV-1 IgG and IgM antibodies respectively among patients with PTB. Also, a higher prevalence of 2.3% has been found among married couples unlike widow group which has zero percent prevalence. Routine screening for HTLV-1 in TB patients may go a long way in exploring as well as better understanding of HTLV-1 infection in Nigeria and a such will provide sufficient tools for prevention and control of HTLV-1 infection.
